Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928772 · ClinicalTrials.gov registry record · Phase 4
Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety
A Phase 4 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 4
- Development phase
- 115
- Enrollment target
NCT00928772: Clinical Trial Phase 4 study, sponsored by University of Oklahoma.
NCT00928772 is a Phase 4 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 115 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928772, a Phase 4 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 115 participants
- Enrollment target
Study Summary
Cranial electro stimulation (CES) provides safe, adequate, side-effect free sedation without excessive drowsiness in preoperative settings.
Primary Outcome
Anxiety was accessed via VAS from 0 to 10 with 10 being the most anxious.
Interventions
- DEVICE CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM
- DRUG MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY
- OTHER NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Why NCT00928772 stopped before completion
NCT00928772 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 3 interventions - of which CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM is the first listed.
NCT00928772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00928772 about?
NCT00928772 is a clinical study titled "Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety". Cranial electro stimulation (CES) provides safe, adequate, side-effect free sedation without excessive drowsiness in preoperative settings.
What is the current status of trial NCT00928772?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2009-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00928772?
The interventions under investigation include: CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM (DEVICE), MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY (DRUG), NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED (OTHER).
Who is sponsoring clinical trial NCT00928772?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00928772's enrollment target sits among peer trials
115 718th of 2000 higher than 1,281 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia